A Point Mutation in the Ubiquitin Ligase RNF170 That Causes Autosomal Dominant Sensory Ataxia Destabilizes the Protein and Impairs Inositol 1,4,5-Trisphosphate Receptor-mediated Ca\textsuperscript{2+} Signaling*

Forrest A. Wright\(^\text{1,2}\), Justine P. Lu\(^\text{1}\), Danielle A. Sliter\(^\text{1}\), Nicolas Dupré\(^\text{1}\), Guy A. Rouleau\(^\text{1}\), and Richard J. H. Wojcikiewicz\(^\text{1,3}\)

From the \(^\text{4}\)Department of Pharmacology, SUNY Upstate Medical University, Syracuse, New York 13210, the \(^\text{5}\)NINDS, National Institutes of Health, Bethesda, Maryland 20892, the \(^\text{6}\)Neuromuscular and Neurogenetic Disease Clinic, CHU de Québec, Laval University, Quebec City, Quebec G1J 1Z4, Canada, and the \(^\text{7}\)Montreal Neurological Institute and Hospital and Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec H3A 2B4, Canada

**Background:** RNF170 is an endoplasmic reticulum membrane ubiquitin ligase that when mutated at arginine 199 causes a neurodegenerative disease.

**Results:** The mutation disrupts salt bridges between transmembrane domains, destabilizes the protein, and inhibits Ca\textsuperscript{2+} signaling via IP\textsubscript{3} receptors.

**Conclusion:** These manifestations of the mutation are likely causative to neurodegeneration.

**Significance:** Understanding the mechanism of action of mutant ubiquitin ligases will lead to better therapies.

RNF170 is an endoplasmic reticulum membrane ubiquitin ligase that contributes to the ubiquitination of activated inositol 1,4,5-trisphosphate (IP\textsubscript{3}) receptors, and also, when point mutated (arginine to cysteine at position 199), causes autosomal dominant sensory ataxia (ADSA), a disease characterized by neurodegeneration in the posterior columns of the spinal cord. Here we demonstrate that this point mutation inhibits RNF170 expression and signaling via IP\textsubscript{3} receptors. Inhibited expression of mutant RNF170 was seen in cells expressing exogenous RNF170 constructs and in ADSA lymphoblasts, and appears to result from enhanced RNF170 autoubiquitination and proteasomal degradation. The basis for these effects was probed via additional point mutations, revealing that ionic interactions between charged residues in the transmembrane domains of RNF170 are required for protein stability. In ADSA lymphoblasts, platelet-activating factor-induced Ca\textsuperscript{2+} mobilization was significantly impaired, whereas neither Ca\textsuperscript{2+} store content, IP\textsubscript{3} receptor levels, nor IP\textsubscript{3} production were altered, indicative of a functional defect at the IP\textsubscript{3} receptor locus, which may be the cause of neurodegeneration. CRISPR/Cas9-mediated genetic deletion of RNF170 showed that RNF170 mediates the addition of all of the ubiquitin conjugates known to become attached to activated IP\textsubscript{3} receptors (monoubiquitin and Lys\textsuperscript{48} and Lys\textsuperscript{63}-linked ubiquitin chains), and that wild-type and mutant RNF170 have apparently identical ubiquitin ligase activities toward IP\textsubscript{3} receptors. Thus, the Ca\textsuperscript{2+} mobilization defect seen in ADSA lymphoblasts is apparently not due to aberrant IP\textsubscript{3} receptor ubiquitination. Rather, the defect likely reflects abnormal ubiquitination of other substrates, or adaptation to the chronic reduction in RNF170 levels.

In eukaryotic cells, ubiquitin ligases (E3)\(^\text{2}\) work together with ubiquitin-conjugating enzymes (E2) to promote ubiquitination of a range of substrates, often leading to their degradation by the proteasome (1–5). Mammals express hundreds of E3s, the vast majority of which contain a RING domain, a motif that appears to provide a docking site for E2s and be necessary for ubiquitin transfer to the substrate (3–5). Endoplasmic reticulum (ER)–associated degradation (ERAD) is the term used to describe the pathway by which aberrant ER lumen or membrane proteins are removed from the cell via ubiquitination and proteasomal degradation (6, 7). A recent bioinformatic survey of RING domain-containing proteins that localize to the ER membrane and that could play a role in ERAD identified a group of 24 E3s (8), some of which (e.g. HRD1) appear capable of mediating the ubiquitination of a broad array of substrates, whereas others (e.g. TRC8) have a much narrower substrate range (3, 6, 7). Furthermore, several of the E3s identified (e.g. RNF170) have yet to be fully characterized (8).

Inositol 1,4,5-trisphosphate receptors (IP\textsubscript{3}Rs) are ER membrane proteins that form tetrameric Ca\textsuperscript{2+} channels that govern ER Ca\textsuperscript{2+} store release (9, 10). When persistently activated, a portion of cellular IP\textsubscript{3}Rs are ubiquitinated and degraded by the proteasome apparently via the ERAD pathway, and this IP\textsubscript{3}R “down-regulation” suppresses Ca\textsuperscript{2+} mobilization (11, 12).

---

\* This work was supported, in whole or in part, by National Institutes of Health Grant DK049194 and the National Ataxia Foundation.

\(\text{1} \text{To whom correspondence should be addressed: 750 E. Adams St., Syracuse, NY 13210. Tel.: 315-464-7956; Fax: 315-464-8014; E-mail: wojcikir@upstate.edu.}\)

---

\(\text{2} \text{The abbreviations used are: E3, ubiquitin ligase; IP}_3, \text{ inositol 1,4,5-trisphosphate; IP}_3R, \text{ inositol 1,4,5-trisphosphate receptor; ER, endoplasmic reticulum; ERAD, ER-associated degradation; ADSA, autosomal dominant sensory ataxia; TM, transmembrane; E2, ubiquitin-conjugating enzyme; PAF, platelet-activating factor; GnRH, gonadotropin-releasing hormone; endo H, endoglycosidase H; [Ca}_2^{2+}, \text{ cytosolic Ca}_2^{2+} \text{ concentration.}\)
Recent studies on the mechanism of IP$_3$R processing by the ERAD pathway have shown that a complex composed of the integral ER membrane proteins erlin1 and erlin2 associates rapidly with activated IP$_3$Rs (11–14), as does RNF170 (15). RNF170 is ~257 amino acids in length, is highly conserved in mammals, is predicted to have 3 transmembrane (TM) domains, with the RING domain facing the cytosol (15, 16), and is constitutively associated with the erlin1/2 complex. RNF170 contributes to IP$_3$R ubiquitination (15), although whether it is responsible for the addition of all of the conjugates that become attached to activated IP$_3$Rs (monoubiquitin and Lys$_{48}$- and Lys$_{63}$-linked ubiquitin chains) (17, 18) is currently unknown. Remarkably, a recent molecular genetic study demonstrated that autosomal dominant sensory ataxia (ADSA), a rare neurodegenerative disease characterized by ataxic gait, reduced sensory perception, and neurodegeneration in the posterior columns of the spinal cord, segregates with an arginine (Arg199) to cysteine mutation on the properties of RNF170 and find that it destabilizes the protein because of disruption of a salt bridge between TM domains 2 and 3, and that mutant RNF170 disrupts Ca$^{2+}$ signaling at the IP$_3$R locus in ADSA lymphoblasts. Genetic deletion of RNF170 revealed that RNF170 mediates the addition of all ubiquitin conjugates to activated IP$_3$Rs and that the ubiquitin ligase activities of wild-type and mutant RNF170 toward activated IP$_3$Rs are apparently identical. Thus, aberrant ubiquitination of other substrates, or cellular adaptation to chronically reduced RNF170 levels likely accounts for the ADSA-associated Ca$^{2+}$ signaling deficit.

**Experimental Procedures**

**Materials**—HeLa cells were cultured as described (13). Human lymphoblast cell lines were isolated from control and affected individuals (16) and cultured in Iscove’s modified Dulbecco’s medium (Thermo Scientific) supplemented with 10% fetal bovine serum, 50 units/ml of penicillin, 50 µg/ml of streptomycin, and 1 mM l-glutamine. Lymphoblasts were cultured in flasks, fed every 2–3 days, and subcultured 1:10 once per week. Lipofectamine plus 4.8 µg of Lipofectamine plus 4.8 µg of total DNA, and 24–48 h later were collected with 155 mM NaCl, 10 mM HEPES, 1 mM EDTA, pH 7.4. Cells were then centrifuged (2,300 g for 1 min), disrupted for 30 min at 4 °C with lysis buffer (150 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA, 1% Triton X-100, 10 µM pepstatin, 0.2 mM PMSF, 0.2 µM soybean trypsin inhibitor, 1 mM dithiothreitol, pH 8.0), centrifuged (16,000 g for 10 min at 4 °C), and supernatant samples were subjected to SDS-PAGE and immunoblotting as described (13–15). For studying the interaction between the erlin1/2 complex and RNF170 by co-immunoprecipitation (15), cells were disrupted using lysis buffer that contained 1% CHAPS instead of Triton X-100. The ubiquitin ligase activity of immunopurified RNF170$^{\text{FLAG}}$ constructs was assessed as described (15).

**Lymphoblasts**—To assess protein expression in cell lysates, lymphoblasts were collected by centrifugation (1,000 × g for 5 min), washed once by resuspension in PBS followed by centrifugation (16,000 × g for 1 min), disrupted for 30 min at 4 °C with 1% CHAPS lysis buffer, centrifuged (16,000 × g for 10 min at 4 °C), and supernatant samples were subjected to SDS-PAGE and immunoblotting as described (13–15). For measurement of the cytosolic free Ca$^{2+}$ concentration ([Ca$^{2+}$])$_{c}$, lymphoblasts were collected by centrifugation (1,000 × g for 1 min), washed once, and then incubated in culture medium at 2 mg of protein/ml with 5 µM fura-2-AM for 1 h at 37 °C, washed 4 times with Krebs HEPES buffer (23), and finally resuspended at 0.5 mg of protein/ml in Krebs HEPES buffer for measurement of [Ca$^{2+}$]$_{c}$ at 37 °C, as described (23). For measurement of IP$_3$ levels, lymphoblasts were collected by centrifugation (1,000 × g for 5 min), washed once by resuspension in RPMI 1640 (Cellgro) followed by centrifugation (1,000 × g for 5 min), resuspended in RPMI 1640 and preincubated at 37 °C for 1 h, then exposed to vehicle (DMSO) or PAF, and IP$_3$ mass was measured as described (23).

**Generation and Analysis of RNF170 Knock-out and Reconstituted Cell Lines**—The CRISPR/Cas9 system (24, 25) was used to target an exon within the mouse RNF170 gene that was common to all predicted splice variants (exon 6). Oligonucleotides that contained the RNF170 target CRISPR sequence (GATACGCGGATACGCGGCTCTG) were annealed and then ligated into AAVI-linearized gRNA vector (Addgene). αT3 mouse pituitary cells were transfected (18) with a mixture of the gRNA construct and vectors encoding Cas9 (Addgene) and EGFP (Clontech). Two days post-transfection, EGFP-expressing cells were selected by fluorescence-activated cell sorting.
Effects of an RNF170 Mutation That Causes Neurodegeneration

and plated at \( \sim 1 \) cell/well in 96-well plates. Colonies were expanded and screened for ablation of RNF170 expression by immunoblotting with anti-RNF170 (raised against amino acids 50–65 of RNF170) (15). Of the cell lines screened, \( \sim 30\% \) lacked RNF170 and 2 of those were expanded for characterization of IP\(_{3}\)R1 processing with essentially identical results; clone IC8 was used for the experiments shown in Fig. 7. Reconstituted cell lines were obtained by transfecting clone IC8 with cDNAs encoding mouse RNF170 and R\(_{199}^{199}\)RNF170 (18), followed by selection in 1.3 mg/ml of G418 for 72 h, plating at \( \sim 1 \) cell/well in 96-well plates, colony expansion, screening with anti-RNF170, and maintenance in 0.3 mg/ml of G418. 2 clones expressing each construct were characterized with essentially identical results.

For analysis of IP\(_{3}\)R1 ubiquitination and protein levels, cells were incubated with 1% CHAPS lysis buffer lacking dithiothreitol, but supplemented with 5 mM N-ethylmaleimide, for 30 min at 4 °C, followed by addition of 5 mM dithiothreitol and centrifugation (16,000 \times g for 10 min at 4 °C). Lysates were then incubated with anti-IP\(_{3}\)R1 to immunoprecipitate IP\(_{3}\)R1 as described (15) and complexes were heated at 37 °C for 30 min prior to SDS-PAGE in 5% gels for ubiquitin conjugate analysis, or 100 °C for 5 min prior to SDS-PAGE in 10% gels for analysis of other proteins. [Ca\(^{2+}\)] was measured as described (23).

Data Presentation—All experiments were repeated at least once, and representative images of gels or traces are shown. Immunoreactivity was detected and quantitated using Pierce ECL reagents and a GeneGnome Imager (Syngene Bio Imaging). Quantitated data are expressed as mean \( \pm \) S.E. or range of \( n \) independent experiments.

Results

Analysis of the Membrane Topology of RNF170—The predicted topology of mouse RNF170, derived from bioinformatic analysis, together with the amino acid sequences of TM domains 2 and 3 are depicted in Fig. 1A. The sequence of human RNF170 is very similar to that of mouse RNF170 (91% identical) and human RNF170 has the same predicted topology (15, 16). Note that Arg\(^{199}\) in the human sequence corresponds to Arg\(^{199}\) in the mouse sequence, because of the absence of Asp\(^{16}\) from the latter (15, 16). The existence of TM domains 2 and 3 was confirmed experimentally, using a series of truncation mutants containing a C-terminal HA/glycosylation tag that together with an assessment of sensitivity to the deglycosylation activity of endo H, can provide information on orientation across the ER membrane (22, 26) (Fig. 1B). That full-length RNF170 (N\(_{267}\)RNF170\(^{199}\)) is insensitive to endo H (and is therefore not glycosylated) localizes the C terminus of this construct to the cytosol (Fig. 1B). In contrast, the sensitivity of N\(_{230}\) RNF170\(^{199}\) to endo H shows that the C terminus of this construct is glycosylated and is within the ER lumen, demonstrating that TM2 traverses the ER membrane (Fig. 1B). Following the same logic, that N\(_{200}\) RNF170\(^{199}\) is insensitive to endo H and is not glycosylated localizes the C terminus of this construct to the cytosol and confirms the orientation of TM2 (Fig. 1B). Finally, to confirm the location of the N terminus, G\(_{8}\) N RNF170\(^{199}\)\(^{199}\) was created, which due to replacement of Gly\(^{8}\) with asparagine, contains an N-glycosylation consensus sequence (NQS) (22, 26) very near the N terminus. This construct was partially glycosylated, indicating that the N terminus is located in the ER lumen (Fig. 1B); that the glycosylation was relatively weak may be because the consensus sequence is suboptimal in comparison to the optimal sequence (NSTMMS) present in the other constructs (22). Overall, these data are consistent with the topology of TM domains 1, 2, and 3 shown in Fig. 1A.

Effects of the Arg\(^{199}\) to Cys mutation on RNF170—Remarkably, the Arg\(^{199}\) to Cys mutation significantly reduced RNF170 expression. This was seen when the mutation was introduced into either untagged RNF170 or RNF170\(^{199}\)\(^{199}\)FLAG (Fig. 2A). Furthermore, the mutants migrated \( \sim 1 \) kDa more rapidly than their wild-type counterparts (Fig. 2A). Additional mutants were made to explore the basis for the reduction in expression and the migration shift, using RNF170\(^{199}\)\(^{199}\)FLAG as a template (Fig. 2B). To examine the possibility that these changes resulted from disulfide bond formation with the newly introduced cysteine,
Effects of an RNF170 Mutation That Causes Neurodegeneration

Arg\textsuperscript{198} was replaced with serine, which is similar in size to cysteine, but which cannot form disulfide bonds. However, \textit{R198C}RNF170\textsc{flag} was also expressed poorly and migrated rapidly (Fig. 2B, lane 4), ruling out a role for disulfide bonds. Likewise, to examine whether the changes were due to loss of the bulky side chain of arginine, or the positive charge, Arg\textsuperscript{198} was replaced with glutamine, which is relatively bulky, but is uncharged, albeit polar. \textit{R198Q}RNF170\textsc{flag} was also expressed quite poorly and migrated rapidly (lane 4), suggesting that it is not the bulk of arginine, but rather its positive charge, that is necessary for normal expression and migration. This was confirmed by replacing Arg\textsuperscript{198} with lysine, which has a slightly shorter side chain, but is still positively charged; \textit{R198K}RNF170\textsc{flag} was expressed and migrated similarly to WT RNF170\textsc{flag} (lane 5).

Examination of the amino acid sequences of TM domains 2 and 3 (Fig. 1A) revealed the presence of an additional arginine in TM2 (Arg\textsuperscript{200}) and two aspartic acids in TM3 (Asp\textsuperscript{231} and Asp\textsuperscript{232}) (Fig. 1A), suggesting that ionic interactions between TM2 and TM3 could be required for wild-type behavior. Mutation of these amino acids confirmed this notion, as R200C RNF170\textsc{flag}, D231A RNF170\textsc{flag}, D232A RNF170\textsc{flag}, and D231A/D232A RNF170\textsc{flag} all expressed poorly and migrated more rapidly than RNF170\textsc{flag} (lanes 6–9). Thus, ionic interactions between arginines in TM2 and aspartic acids in TM3 appear to be required for normal expression of RNF170. Furthermore, it appears that 2 charged amino acids in each TM are required for normal expression, because mutation of one arginine and one aspartic acid in \textit{R198C/D231A} RNF170\textsc{flag} did not rescue expression (lane 10). Finally, it is noteworthy that accelerated migration correlated well with reduced expression (Fig. 2B) and was caused by both arginine and aspartic acid loss and is therefore not due to a change in net protein charge. Rather, these data, together with the fact that RNF170 migrates at 21.5 kDa rather than the predicted 30 kDa (15), suggest that RNF170 is not fully denatured during SDS-PAGE and that the mutations affect the structural organization that is retained. The mutations may also alter the structure of RNF170 \textit{in vivo}, which in turn, could account for the reductions in expression, perhaps because of protein destabilization.

**Mechanism of Reduced Expression**—To explore possible destabilization mechanisms, we examined the effects of the proteasome inhibitor MG-132. When incubated with cells expressing exogenous RNF170\textsc{flag} constructs (Fig. 3A), MG-132 caused a marked accumulation of \textit{R198C}RNF170\textsc{flag} (lanes 4–6), although leaving WT RNF170\textsc{flag} levels essentially unaltered (lanes 1–3). Thus, the proteasome appears to mediate the reduced expression of \textit{R198C}RNF170\textsc{flag}. Furthermore, as E3 autoubiquitination is a commonly observed phenomenon (27), we examined the effects of inactivating ligase activity on \textit{R198C}RNF170\textsc{flag} expression. Previously, we have shown that mutation of Cys\textsuperscript{101} and His\textsuperscript{103} in the RING domain of mouse RNF170 blocks ubiquitin ligase activity (15), and introduction of these mutations into \textit{R198C}RNF170\textsc{flag} (creating \textit{R198C/ARING}RNF170\textsc{flag}) normalized expression (Fig. 3B, lane 4), suggesting that ligase activity, and most likely autoubiquitination, mediates the reduced expression of \textit{R198C}RNF170\textsc{flag}. Interestingly, the \textit{R198C/ARING}RNF170\textsc{flag} mutant still migrated faster than WT RNF170\textsc{flag}, suggesting that the putative structural change has not been reversed by mutation of the RING domain (Fig. 3B, lane 4). A role for autoubiquitination was supported by the observation that WT RNF170\textsc{ha} expression was not differentially affected by co-expression of WT RNF170\textsc{flag} and \textit{R198C}RNF170\textsc{flag} (Fig. 3C, lanes 2 and 3); this result shows that the apparent destabilizing effect of the R198C mutation is intramolecular and is not transmitted to co-expressed WT RNF170\textsc{ha} molecules. Importantly, \textit{R198C}RNF170\textsc{flag} exhibited \textit{in vitro} ubiquitin ligase activity similar to that of WT RNF170\textsc{flag} (Fig. 3D, lanes 2 and 4), indicating that it is fully capable of autoubiquitinating. Finally, to determine protein half-lives, transfected cells were incubated with the protein synthesis inhibitor cycloheximide (Fig. 3E). This revealed that the half-life of \textit{R198C}RNF170\textsc{flag} is much shorter than that of WT RNF170\textsc{flag} and that MG-132 blocks \textit{R198C}RNF170\textsc{flag} degradation. Overall, these data indicate that the R198C mutation decreases RNF170 expression by triggering the molecule to autoubiquitinate and then be degraded by the proteasome.
The R198C Mutation Does Not Alter Membrane Topology, Subcellular Localization, or Interaction with the Erлин1/2 Complex—To explore why mutation-induced salt bridge disruption triggers RNF170 autoubiquitination, we first examined whether subcellular localization was altered. However, the extent of N-glycosylation seen for the relevant constructs shown in Fig. 1B (N267RNF170HA and N230RNF170HA) was not substantially altered by introduction of the R198C mutation (Fig. 4A), indicating that localization to the ER and insertion of TM domains is normal. Likewise, interaction with the endogenous erлин1/2 complex was normal, because immunoprecipitation with anti-erлин2 (15) recovered WTRNF170HA and R198CRNF170HA equally well (Fig. 4B). Furthermore, membrane association was normal, as both WTRNF170HA and

FIGURE 3. The R198C mutation reduces RNF170 expression via autoubiquitination and the proteasome. A-C, cDNAs encoding tagged WT and mutant RNF170 constructs transfected into HeLa cells were treated as indicated, and cell lysates were probed with anti-FLAG or anti-HA to recognize exogenous RNF170 constructs, or anti-erлин2, which served a loading control. The histograms show combined quantitated immunoreactivity (mean ± S.E., n = 4). D, RNF170FLAG constructs were immunopurified from transfected HeLa cells and incubated with E1 (UBE1), E2 (UbcH5b), and HA-ubiquitin as indicated for 30 min at 30 °C, with the exception of lane 1, which lacked E2. Samples were then probed with anti-HA to assess ubiquitination (upper panel), or anti-FLAG to assess the levels of RNF170FLAG constructs (lower panel). The asterisk marks a background band. E, transfected HeLa cells were treated as indicated with 20 μg/ml of cycloheximide (CHX), without or with 10 μM MG-132. Cell lysates were then probed with anti-p53 as a positive control for cycloheximide action, anti-p97 as a loading control, and anti-FLAG to recognize exogenous RNF170 constructs (long and short exposures are shown to facilitate visualization of immunoreactivity changes). The graph shows combined quantitated FLAG immunoreactivity, using the long exposure for R198CRNF170FLAG and the short exposure for WT-RNF170FLAG (mean ± range, n = 2).
Effects of an RNF170 Mutation That Causes Neurodegeneration

FIGURE 4. Lack of effect of the R198C mutation on RNF170 membrane association and topology, and interaction with the erlin1/2 complex. cDNAs encoding HA-tagged WT and mutant RNF170 constructs were transfected into HeLa cells. A, N-glycosylation of N267/R198CRNF170HA and N230/H11011R198CRNF170HA, R198C-containing versions of the constructs shown in Fig. 1A, was assessed as described in the legend to Fig. 18. B, interaction with the erlin1/2 complex. Erlin1/2 complex was immunoprecipitated with anti-erlin2 and probed for R199CRNF170, R198C-containing versions of the constructs shown in Fig. 1B, was assessed as described in the legend to Fig. 1A. Anti-erlin2 and anti-HA were used to probe the input lysate and the amounts in input lysates, indicating that they interact with the erlin1/2 complex equally well. C, cells were lysed and centrifuged into cytosol (C) and membrane (M) factions as described (13), and probed as indicated.

R198C-RNF170HA were fractionated with membranes (Fig. 4C). Thus, the R198C mutation does not dramatically alter the localization of RNF170, indicating that a subtle change in its properties (e.g. in the way that it folds) accounts for its apparent autoubiquitination and proteasomal degradation.

RNF170 Expression in Control and ADSA-affected Individuals—Lymphoblast lines from control and ADSA-affected individuals were examined for RNF170 expression (Fig. 5A). In controls, an anti-RNF170 immunoreactive band at ~21.5 kDa was observed (lanes 1–3), the same size as endogenous HeLa cell RNF170 and untagged mouse RNF170 (Fig. 2A). Remarkably, in affected lymphoblasts the strength of the 21.5-kDa band was reduced and an additional weaker band at ~20.5 kDa was also observed (lanes 4–6). These results are consistent with the expression level and migration differences seen between exogenous mouse WT-RNF170 and R198CRNF170 (Fig. 2A) and between exogenous human WT-RNF170 and R199CRNF170 (Fig. 5B), and with the knowledge that affected individuals are heterozygote (16). Thus, it appears that the R199CRNF170 encoded by the mutant allele in affected individuals migrates at ~20.5 kDa and is relatively poorly expressed. This leads to an ~27% reduction in total RNF170 immunoreactivity in affected lymphoblasts (Fig. 5A).

Ca2+ Mobilization via IP3 Receptors Is Impaired in Affected Lymphoblasts—Because IP3Rs are the only known substrates for RNF170 (15), we examined whether IP3R function was different in control and affected lymphoblasts, using PAF to trigger IP3,R-mediated Ca2+ mobilization (28) (Fig. 6). Remarkably, PAF-induced increases in [Ca2+]i were significantly suppressed in affected lymphoblasts (Fig. 6A), suggesting that IP3,R-mediated Ca2+ mobilization might be impaired, although the suppression could also be due to an effect on Ca2+ entry (29). To rule out any role for Ca2+ entry, EGTA was added immediately prior to PAF to chelate extracellular Ca2+ to ~100 nm (23), and under these conditions the suppression of PAF-induced increases in [Ca2+]i was still clearly evident (Fig. 6B). To examine if the suppression results from ER Ca2+ stores being smaller, cells were exposed to the sarcoplasmic reticulum Ca2+-APTase pump inhibitor thapsigargin, which allows Ca2+ leak from the ER in an IP3-independent manner (30). However, thapsigargin caused the same [Ca2+]i increase in control and affected lymphoblasts (Fig. 6C), indicating that Ca2+ stores are of equal size. Likewise, reduced IP3 formation was not the reason for the suppression, as PAF-induced increases in IP3 mass were the same in control and affected lymphoblasts (Fig. 6D), overall, these data indicate that Ca2+ mobilization via IP3Rs is impaired in affected lymphoblasts, but not because of a change in Ca2+ store size, or the abundance of IP3Rs, and point toward a mechanism that involves a regulation of IP3R activity.

Ubiquitin Ligase Activity of RNF170 and R198CRNF170 in Cells—R198CRNF170 exhibits apparently normal ubiquitin ligase activity in vitro when mixed with purified enzymes (Fig. 3D), but that tells us almost nothing about how its activity might differ from that of WT-RNF170 in vivo, where the intracellular milieu contains a full complement of E2s, substrates, and other factors. To date, endogenous activated IP3Rs are the only known substrates for RNF170 (15), but it has yet to be resolved whether RNF170 is responsible for the addition of all of the ubiquitin conjugates that become attached to activated IP3Rs, or just some (17, 18). Initially, we sought to compare the ligase activities of WT-RNF170 and R199CRNF170 toward IP3Rs in control and ADSA lymphoblasts, but pilot experiments showed that to be unfeasible, primarily because of the paucity of IP3Rs therein (data not shown). Thus, we employed α3T3 cells, the cells in which we first identified RNF170 (15) and that exhibit very robust IP3,R ubiquitination in response to the IP3 generating cell surface receptor agonist GnRH (17, 18). First, to determine which ubiquitin conjugates RNF170 confers onto RNF170KO cells. Interestingly, IP3,R1 expression was enhanced ~65% by RNF170 deletion (Fig.
Effects of an RNF170 Mutation That Causes Neurodegeneration

A

B

FIGURE 5. RNF170 levels in lymphoblasts from control and ADSA-affected individuals. A, lysates from 3 control (lanes 1–3) and 3 affected individuals (lanes 4–6) were probed with anti-RNF170 and anti-erlin2. For the panels shown, immunoreactivity was quantitated and is plotted as total RNF170/erlin2 immunoreactivity (arbitrary units). Multiple quantitations of total RNF170 immunoreactivity from these and other lymphoblast lines showed that affected individuals contained 73 ± 5% of the immunoreactivity seen in control lymphoblasts (n ≥ 5). B, cDNAs encoding human WT-RNF170ΔA and R199CRNF170ΔA were transfected into HeLa cells and cell lysates were probed as indicated. Erlin2 served as a loading control.

FIGURE 6. Assessment of the IP3-mediated Ca2+ signaling pathway in lymphoblasts. Multiple control and affected lymphoblast cell lines (n) were analyzed. A–C, fura2-loaded cells were exposed to PAF, EGTA, and thapsigargin (TG) as indicated and [Ca2+]i was calculated. Values in parentheses are mean ± S.E. of PAF- or TG-induced increases in [Ca2+]i over basal values (n ≥ 4, with * indicating p < 0.05 when comparing values from control versus affected cells). D, lysates from 4 control and 4 affected lymphoblast lines were probed for the proteins indicated. Total IP3R immunoreactivity in control and affected lymphoblasts, measured with anti-IP3R1–3 (lowest panel), was 80 ± 20 and 76 ± 15 arbitrary units, respectively (mean ± S.E.).

7, A and D), indicating that in addition to its role in mediating the degradation of activated IP3Rs (15), RNF170 also plays a role in basal IP3R1 turnover. Ca2+ mobilization in αT3 RNF170KO cells in response to GnRH was normal (Fig. 7B), indicating that the IP3-dependent signaling pathway and IP3R activation are not perturbed by the absence of RNF170. Remarkably, deletion of RNF170 completely blocks GnRH-induced IP3R1 ubiquitination (Fig. 7C), observed using either FK2 antibody, which detects all ubiquitin conjugates (monoubiquitin, and Lys48- and Lys63-linked chains), or antibodies specific for Lys48- and Lys63-linked chains (18). In contrast, erlin2 association with IP3R1 was not blocked, indicating that association of the erlin1/2 complex with activated IP3R1 is unimpaired, consistent with the notion that it is the erlin1/2 complex that recruits RNF170 to activated IP3R1, rather than vice versa (12, 15). Thus, RNF170 does indeed catalyze the formation of all ubiquitin conjugates on activated IP3R1, and as would be expected, GnRH did not cause IP3R down-regulation in αT3 RNF170KO cells (Fig. 7D).

To directly assess the ligase activity of R198CRNF170, we sought to reconstitute IP3R ubiquitination in αT3 RNF170KO cells by stably expressing exogenous RNF170 constructs (Fig. 7E). Cell lines were obtained, although exogenous expression was less than that seen for endogenous RNF170 in control αT3 cells (data not shown). Both WT-RNF170 and R198CRNF170 were capable of ubiquitinating activated IP3R, as indicated by increases in Lys48- and Lys63-linked ubiquitin chains and total ubiquitin after exposure to GnRH (Fig. 7E). That less ubiquitination was seen in R198CRNF170-expressing cells is most likely a consequence of lower expression level and IP3R binding of the mutant (Fig. 7E). Thus, the ligase activity of R198CRNF170 in vivo appears to be qualitatively normal, and aberrant IP3R receptor ubiquitination is unlikely to account for the Ca2+ signaling deficit seen in ADSA lymphoblasts.

Discussion

Our data show that the Arg198 to Cys mutation in mouse RNF170 reduces the stability and expression level of the protein. The mutation appears to disrupt a salt bridge between TM domains 2 and 3 and leads to autoubiquitination and enhanced turnover via the ubiquitin-proteasome pathway. This mechanism also likely applies to human R199CRCNF170 in ADSA-affected individuals, and accounts for the ∼27% reduction in the total cellular complement of RNF170. An equivalent decrease in cellular ligase activity attributable to RNF170 is likely, which could be critical to development of the disease. Alternatively, the ligase activity of mutant RNF170 in vivo could be abnormal.
We did not obtain support for this notion from studies with purified components in vitro (Fig. 3D), or from analysis of IP3R1 ubiquitination in vivo (Fig. 7E), but that does not rule out the possibility that mutant RNF170 acts abnormally toward other substrates. Mutant RNF170 acting in this manner (i.e., dominantly) would be consistent with zebrafish studies, in which expression of exogenous mutant RNF170 causes aberrant development (16).

Prior to the current study, our approach to defining the function of RNF170 (and other proteins suspected to play a role in IP3R ERAD) has been to deplete them using RNA interference. Although we have had some success with this approach (13–15, 31) it has major limitations; in particular, proteins are only depleted and the effects of residual proteins are hard to assess and complicate interpretation of data from reconstitution experiments, and cells expressing short interfering RNA are often unhealthy and are available only in limited quantities. Use of the CRISPR/Cas9 system (24, 25) allowed us to delete RNF170 and demonstrate, for the first time, that RNF170 catalyzes the addition of all ubiquitin conjugates to activated IP3R1. Intriguingly, this suggests that RNF170 interacts with multiple E2s, most likely Ubc13 and Ubc7, because Ubc13 is the only E2 known to build Lys63-linked chains (5, 32) and Ubc7, which builds Lys48-linked

---

FIGURE 7. CRISPR/Cas9-mediated deletion of RNF170 and reconstitution with exogenous RNF170 constructs. A, levels of RNF170, IP3R1, and other pertinent proteins in lysates from αT3 control and RNF170KO cells. B, GnRH (0.1 μM)-induced Ca2+ mobilization in αT3 control and RNF170KO cells. C, IP3R1 ubiquitination in αT3 control and RNF170KO cells. Cells were incubated with 0.1 μM GnRH and anti-IP3R1 IPs and input lysates were probed for the proteins indicated. D, IP3R1 down-regulation in αT3 control and RNF170KO cells. Cells were incubated with 0.1 μM GnRH and lysates were probed for the proteins indicated. The histogram shows combined quantitated immunoreactivity (mean ± S.E., n = 4). E, reconstitution of IP3R1 ubiquitination in RNF170KO cells. αT3 RNF170KO cells stably expressing WT RNF170 or R198C RNF170 were incubated without or with 0.1 μM GnRH for 20 min, and anti-IP3R1 IPs were probed for the proteins indicated.
Effects of an RNF170 Mutation That Causes Neurodegeneration

chains (5, 32), is already strongly implicated in mediating IP$_3$R1 ubiquitination and degradation (33).

Why does the Arg$^{198}$ to Cys mutation destabilize RNF170? It appears that a network of salt bridges couple TM domains 2 and 3 together, because mutation of either Arg$^{198}$ or Arg$^{200}$ in TM2 reduces protein expression, as do mutations to Asp$^{331}$ and Asp$^{332}$ in TM3. A hint as to why these mutations are apparently destabilizing is provided by the fact that they also cause RNF170 to migrate more rapidly on SDS-PAGE, indicative of a structural change in the protein that either causes more compact folding and/or alters interactions with SDS. The structural change appears to be subtle, as the Arg$^{198}$ to Cys mutation did not significantly affect TM2 and TM3 insertion into the ER membrane, or interaction with the erlin1/2 complex, but could still be sufficient to trigger autoubiquitination and targeting for ERAD. Interestingly, many other E3s are known to be regulated by ubiquitination (3, 27), including the ER membrane ligase gp78 (27), which is relatively unstable and is controlled both by autoubiquitination and an additional ER membrane ubiquitin ligase Hrd1 (27). It will be interesting to see whether mutations in the TM domains of gp78 and other ER membrane ligases (8) are also destabilizing.

Although the presence of charged residues in TM domains is energetically unfavorable, such residues are often found therein, where they play important functions, often involving salt bridges (34). Intriguingly, TM domain-located charged residues are those most likely to cause disease when mutated, arginine has the highest propensity for disease causation, and the Arg to Cys mutation is relatively common because cytosine to thymine transition occurs with relatively high frequency (35). Situations very similar to that described here for RNF170 are seen in other proteins. For example, the pore architecture of cystic fibrosis transmembrane conductance regulator is maintained by salt bridges between arginines in TM6 (Arg$^{347}$ and Arg$^{352}$) and aspartic acids in adjacent TMs (36), and naturally occurring, charge altering mutations of Arg$^{352}$ cause cystic fibrosis (37). Likewise, the naturally occurring R279C mutation in the prostacyclin receptor dramatically reduces protein expression (38).

Remarkably, the expression of R199C-RNF170 correlated with a reduction in PAF-induced Ca$^{2+}$ mobilization in lymphoblasts that was not due to a change in IP$_3$R levels, but rather appears to result from reduced signal transduction efficiency at the IP$_3$R locus. This was apparently not due to aberrant IP$_3$R ubiquitination, as the ubiquitination of activated IP$_3$R1 in cells expressing wild-type or mutant RNF170 was qualitatively identical, at least in terms of the addition of total ubiquitin and Lys$^{48}$- and Lys$^{63}$-linked chains. Rather, the reduction in signal transduction efficiency at the IP$_3$R locus could be an indirect effect, if RNF170 turns out to ubiquitinate additional substrates (e.g. proteins that regulate IP$_3$Rs), or if long-term adaptation to the ~27% reduction in total RNF170 expression seen in ADSA lymphoblasts alters the expression of genes that govern Ca$^{2+}$ signaling.

Dysregulation of Ca$^{2+}$ metabolism and IP$_3$R function is often mooted to be the cause of the neurodegeneration that underpins certain spinocerebellar ataxias and neurodegenerative diseases (39 – 43) and our data suggest that the same could be true for ADSA. If so, therapies aimed at boosting Ca$^{2+}$ mobilization could be contemplated, similarly to the way that manipulating Ca$^{2+}$ metabolism is being examined as a therapy for Huntington disease and other spinocerebellar ataxias (41 – 43). Interestingly, mutations to erlin2 also cause neurodegenerative diseases (44 – 47). Erlin2 is the dominant partner in the erlin1/2 complex, to which RNF170 is constitutively associated (11, 12, 15), and the erlin1/2 complex mediates the interaction of RNF170 with IP$_3$Rs (15). Clearly, defining the mechanisms by which mutations to the erlin1/2 complex-RNF170 axis cause neurodegeneration will be fascinating topics for future study. Acknowledgments—We thank Erik Vandermark and Jacquelyn Schulman for helpful suggestions.

References

1. Finley, D. (2009) Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem. 78, 477–513
2. Kleiger, G., and Mayor, T. (2014) Perilous journey: a tour of the ubiquitin-proteasome system. Trends Cell Biol. 24, 352–359
3. Deshaies, R. J., and Joazeiro, C. A. (2009) RING Domain E3 ubiquitin ligases. Annu. Rev. Biochem. 78, 399–434
4. Buddidarmo, R., Nakatani, Y., and Day, C. L. (2012) RINGs hold the key to ubiquitin transfer. Trends Biochem. Sci. 37, 58–65
5. Metzger, M. B., Pruneda, J. N., Klevit, R. E., and Weissman, A. M. (2014) RING-type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination. Biochim. Biophys. Acta 1843, 47–60
6. Ruggiano, A., Foresti, O., and Carvalho, P. (2014) ER-associated degradation: protein quality control and beyond. J. Cell Biol. 204, 869–879
7. Christianson, J. C., and Ye, Y. (2014) Cleaning up in the endoplasmic reticulum: ubiquitin in charge. Nat. Struct. Mol. Biol. 21, 325–335
8. Neutzner, A., Neutzner, M., Benischke, A. S., Ryu, S. W., Frank, S., Youle, R. J., and Karbowski, M. (2011) A systematic search for endoplasmic reticulum (ER) membrane-associated RING finger proteins identifies Nixoni/ZNR4 as a regulator of calnexin stability and ER homeostasis. J. Biol. Chem. 286, 8633–8643
9. Foskett, J. K., White, C., Cheung, K. H., and Mak, D. O. (2007) Inositol trisphosphate receptor Ca$^{2+}$ release channels. Physiol. Rev. 87, 593–658
10. Seo, M. D., Velamakanni, S., Ishiyama, N., Stathopulos, P. B., Rossi, A. M., Khan, S. A., Dale, P., Li, C., Ames, J. B., Ikura, M., and Taylor, C. W. (2011) Structural and functional conservation of key domains in InsP$_3$ and ryanodine receptors. Nature 483, 108–112
11. Wojcikiewicz, R. J., Pearce, M. M., Slier, D. A., and Wang, Y. (2009) When worlds collide: IP$_3$ receptors and the ERAD pathway. Cell Calcium 46, 147–153
12. Wojcikiewicz, R. J. (2012) Inositol 1,4,5-trisphosphate receptor degradation pathways. WIREs Membr. Transp. Signal. 1, 126–135
13. Pearce, M. M., Wang, Y., Kelley, G. G., and Wojcikiewicz, R. J. (2007) SPFH2 mediates the endoplasmic reticulum-associated degradation of inositol 1,4,5-trisphosphate receptors and other substrates in mammalian cells. J. Biol. Chem. 282, 20104–20115
14. Pearce, M. M., Wormer, D. B., Wilkens, S., and Wojcikiewicz, R. J. (2009) An endoplasmic reticulum (ER) membrane complex composed of SPFH1 and SPFH2 mediates the ER-associated degradation of inositol 1,4,5-trisphosphate receptors and other substrates in mammalian cells. J. Biol. Chem. 282, 10433–10445
15. Lu, J. P., Wang, Y., Slier, D. A., Pearce, M. M., and Wojcikiewicz, R. J. (2011) RNF170, an endoplasmic reticulum membrane ubiquitin ligase, mediates inositol 1,4,5-trisphosphate receptor ubiquitination and degradation. J. Biol. Chem. 286, 24426–24433
16. Valdmanis, P. N., Dupré, N., Lachance, M., Stochmanski, S. J., Belzil, V. V., Dion, P. A., Thiffault, I., Brais, B., Weston, L., Saint-Amant, L., Samuels, M. E., and Rouleau, G. A. (2011) A mutation in the RNF170 gene causes autosomal dominant sensory ataxia. Brain 134, 602–607
17. Slier, D. A., Kubota, K., Kirkpatrick, D. S., Alzayady, K. J., Gygí, S. P., and Wojcikiewicz, R. J. (2008) Mass spectral analysis of type I inositol 1,4,5-trisphosphate receptor ubiquitination. J. Biol. Chem. 283, 35319–35328
18. Slier D. A., Aguier, M., Gygí, S. P., and Wojcikiewicz, R. J. (2011) Activated inositol 1,4,5-trisphosphate receptors are modified by homogene-
ous Lys-48- and Lys-63-linked ubiquitin chains, but only Lys-48-linked chains are required for degradation. J. Biol. Chem. 286, 1074–1082
19. Moeller, J. J., Macaulay, R. J., Valdmanis, P. N., Weston, L. E., Rouleau, G. A., and Dupré, N. (2008) Autosomal dominant sensory ataxia: a neuroaxonal dystrophy. Acta Neuropathol. 116, 331–336
20. Wojcikiewicz, R. J. (1995) Type I, II and III inositol 1,4,5-trisphosphate receptors are unequally susceptible to down-regulation and are expressed in markedly different proportions in different cell types. J. Biol. Chem. 270, 11676–11683
21. Bultynck, G., Szulcik, K., Kasri, N. N., Assefa, Z., Callewaert, G., Missiaen, L., Parys, J. B., and De Smedt, H. (2004) Thimerosal stimulates Ca2+ flux through inositol 1,4,5-trisphosphate receptor type 1, but not type 3, via modulation of an isoform-specific Ca2+-dependent intramolecular interaction. Biochem. J. 381, 87–96
22. Baño-Polo, M., Baldin, F., Tamborero, S., Marti-Renom, M. A., and Minagar, I. (2011) N-glycosylation efficiency is determined by the distance to the C-terminus and the amino acid preceding an Asn-Asp-Thr sequon. Protein Sci. 20, 179–186
23. Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., and Church, G. M. (2013) RNA-guided human genome engineering via Cas9. Science 339, 823–826
24. van Geest, M., and Lolkema, J. S. (2000) Membrane topology and insertion of membrane proteins: search for topogenic signals. Microbiol. Mol. Biol. Rev. 64, 13–33
25. Weissman, A. M., Shabek, N., and Ciechanover, A. (2011) The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nat. Rev. Mol. Cell Biol. 12, 605–620
26. Pietruck, F., Spleiter, S., Daul, A., Philipp, T., Derwahl, M., Schatz, H., and Siffert, W. (1998) Enhanced G protein activation in IDDM patients with diabetic nephropathy. Diabetologia 41, 94–100
27. Roskopf, D., Daelman, W., Busch, S., Schurks, M., Hartung, K., Kribben, A., Michel, M. C., and Siffert, W. (1998) Growth factor-like action of lysophosphatidic acid on human B lymphoblasts. Ann. J. Physiol. 274, C1573–1582
28. Thastrap, O., Cullen, P. J., Drebak, B. K., Hanley, M. R., and Dawson, A. P. (1990) Thapsigargin, a tumour promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2+-ATPase. Proc. Natl. Acad. Sci. U.S.A. 87, 2466–2470
29. Alzayady, K. J., Panning, M. M., Kelley, G. G., and Wojcikiewicz, R. J. (2005) Involvement of the p97-Ufd1-Npl4 complex in the regulated endoplasmic reticulum-associated degradation of inositol 1,4,5-trisphosphate receptors. J. Biol. Chem. 280, 34530–34537
30. Ye, Y., and Rape, M. (2009) Building ubiquitin chains: E2 enzymes at work. Nat. Rev. Mol. Cell Biol. 10, 755–764
31. Webster, J. M., Tiwari, S., Weissman, A. M., and Wojcikiewicz, R. J. (2003) Inositol 1,4,5-trisphosphate receptor ubiquitination is mediated by mammalian Ubc7, a component of the endoplasmic reticulum-associated degradation pathway, and is inhibited by chelation of intracellular Zn2+. J. Biol. Chem. 278, 38238–38246
32. von Heijne, G. (2006) Membrane-protein topology. Nat. Rev. Mol. Cell Biol. 7, 909–918
33. Partridge, A. W., Therien, A. G., and Deber, C. M. (2004) Missense mutations in transmembrane domains of proteins: phenotypic propensity of polar residues for human disease. Proteins 54, 648–656
34. Cui, G., Freeman, C. S., Knotts, T., Prince, C. Z., Kuang, C., and McCarty, N. A. (2013) Two salt bridges differentially contribute to the maintenance of cystic fibrosis conductance regulator (CFTR) channel function. J. Biol. Chem. 288, 20758–20767
35. Cui, G., Zhang, Z.-R., O’Brien, A. R., Song, B., and McCarty, N. A. (2008) Mutations at arginine 352 alter the pore architecture of CFTR. J. Membr. Biol. 222, 91–106
36. Stitham, J., Arehart, E., Gleim, S. R., Li, N., Douville, K., and Hwa, J. (2007) New insights into human prostacyclin receptor structure and function through natural and synthetic mutations of transmembrane charged residues. Br. J. Pharmacol. 152, 513–522
37. Paulson, H. L. (2009) The spinocerebellar ataxias. J. Neuroophthalmol. 29, 227–237
38. Matilla-Dueñas, A., Corral-Juan, M., Volpini, V., and Sanchez, I. (2012) The spinocerebellar ataxias: clinical aspects and molecular genetics. Adv. Exp. Med. Biol. 724, 351–374
39. Foskett, J. K. (2010) Inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington’s disease and spinocerebellar ataxias. Neurochem. Res. 36, 1186–1197
40. Foskett, J. K. (2010) Inositol trisphosphate receptor Ca2+ release channels in neurodegenerative diseases. Physiol. Rev. 90, 481–494
41. Brown, S. A., and Loew, L. M. (2014) Integration of modeling with experimental and clinical findings synthesizes and refines the central role of inositol 1,4,5-trisphosphate receptor 1 in spinocerebellar ataxia. Front. Neurosci. 8, 453
42. Yildirim, Y., Orhan, E. K., Iseri, S. A., Serdaroğlu-Oflazer, P., Kara, B., Solakoglu, S., and Tolun, A. (2011) A frameshift mutation of erlin2 in recessive intellectual disability, motor dysfunction and multiple joint contractures. Hum. Mol. Genet. 20, 1886–1892
43. Alazami, A. M., Adly, N., Al Dhalaan, H., and Alkuraya, F. S. (2011) A nullimorphic erlin2 mutation defines a complicated hereditary spastic paraplegia locus (SPG18). Neurogenetics 12, 333–336
44. Al-Saif, A., Bohlega, S., and Al-Mohanna, F. (2012) Loss of erlin2 function leads to juvenile primary lateral sclerosis. Ann. Neurol. 72, 510–516
45. Waki, S. M., Bohlega, S., Hagos, S., Baz, B., Al Dossari, H., Ramzan, K., and Al-Hassan, Z. N. (2013) A novel splice site mutation in erlin2 causes hereditary spastic paraplegia in a Saudi family. Eur. J. Med. Genet. 56, 43–45